Thanks for joining DividendStocks.com, the daily newsletter built for dividend and income investors like you. We’re thrilled to have you on board and can’t wait to help you discover the best dividend opportunities out there. Before we can start sending your daily insights, please take a quick moment to confirm your subscription: Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Why wait? Let’s get your dividend journey started! Click Here to Start Discovering Top Income-Generating Stocks See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Further Reading from MarketBeat.com Pfizer Adds to Its Big Bet on Weight Loss DrugsWritten by Jordan Chussler. Published 12/16/2025. 
Key Points - The health care sector has led the S&P 500 over the three months, but Pfizer has lagged of late, slipping 5% since the start of October.
- As the Big Pharma company continues to struggle to replace COVID-19 vaccine revenue, it is heavily learning into the semaglutide and GLP-1 weight loss drug trend.
- Last week, the company signed a $2.1 billion licensing agreement with a Chinese pharma company to develop its early-stage weight loss pill.
Health care stocks have been on a run lately, leading the S&P 500's 11 sectors over the past three months with a gain of 11.55%. Unfortunately for some investors, that recent rally has not included all of the Big Pharma mainstays. Pfizer (NYSE: PFE), the maker of Chantix, Eliquis and Paxlovid, has seen its shares slide 5% since the start of October. By comparison, other mega-cap pharmaceutical companies such as Johnson & Johnson (NYSE: JNJ), Regeneron Pharmaceuticals (NASDAQ: REGN), and Eli Lilly (NYSE: LLY) are up nearly 14%, 24%, and 25%, respectively, over the same time frame. REVEALED: America just unlocked a $500 trillion asset
Everyone's talking about AI stocks but almost no one is talking about what AI actually runs on.
Nickel. Copper. Cobalt. Manganese.
America just secured exclusive rights to the largest untapped supply on Earth.
One company is already in position and this could be one of the most important AI infrastructure plays heading into 2026. The name and ticker are available here now >>> And despite Pfizer making headlines on Nov. 13 after acquiring obesity biotech Metsera in a $10 billion deal, the stock has only mustered a 0.23% gain since then. But the nearly 177-year-old biopharma company is once again looking to expand its role in the weight loss drug market, with management and shareholders alike hoping that doing so can help it recover lost revenue as demand for mRNA COVID-19 vaccines wanes. Pfizer Looks to Gain Market Share After Enormous Deal With YaoPharma On Tuesday, Dec. 9, Pfizer struck a $2.1 billion licensing deal with China's YaoPharma to develop a GLP-1 weight-loss pill that is in early-stage development. The drug works similarly to Wegovy, the game-changing weight-loss injection from competitor Novo Nordisk (NYSE: NVO). News of a yet-to-be-approved pill may not move the stock in the short term, but it does reflect the company's commitment to the obesity treatment market. Under the agreement, Pfizer will pay a $150 million upfront fee to YaoPharma's parent company, Shanghai Fosun Pharmaceutical, which has an $8.4 billion market cap. Pfizer could also pay up to $1.94 billion in milestone payments if the drug meets development and approval milestones, plus royalties on future sales if and when the drug is approved. Those milestone payments are contingent on YaoPharma successfully navigating early-stage trials, with Pfizer taking control of later-stage development. Pfizer also plans to conduct combination studies — currently in mid-stage development — pairing the Chinese firm's pill with Pfizer's own GIP (a gut hormone) receptor program, an approach Eli Lilly has adopted with Zepbound and Mounjaro to target both GLP-1 and GIP. Pfizer Is Positioning Itself for the Future of the Weight Loss Drug Market The deal underscores how aggressively Pfizer's executives are pursuing a long-term position in the GLP-1 and broader obesity-treatment market. Including the Metsera acquisition and the YaoPharma licensing deal, Pfizer has committed roughly $12.1 billion over the past month as it pursues opportunities in a rapidly growing industry. Forecasts from market analysis firm Grand View Research suggest the GLP-1 weight-loss drug market could grow at a compound annual growth rate (CAGR) of 18.54% from 2025 to 2030 — expanding from under $14 billion at the start of this year to an estimated $48.84 billion by 2030. Grand View also found that North America accounts for the largest revenue share, with more than 75% of the GLP-1 agonists market. While other obesity interventions exist, including lifestyle changes and bariatric surgery, GLP-1 drugs remain the preferred option among many physicians and patients. Patient Investors Can Enjoy PFE's Sizable Dividend Shareholders are hoping Pfizer's push into the weight-loss market proves fruitful after the stock delivered a loss of more than 31% over the past five years. Much of that decline stemmed from reduced COVID-vaccine sales, which drove revenue growth from gains of more than 95% at the end of 2021 to a contraction of over 41% by the end of 2023. Last year, Pfizer rebounded modestly, recording nearly a 7% increase in revenue. At the same time, the stock's dividend has offset some investors' concerns. Pfizer remains a strong dividend payer with a current yield of 6.65% — $1.72 per share annually. That payout has increased for 16 consecutive years, making the stock attractive to income investors despite a payout ratio near 100% that raises questions about sustainability. For investors willing to take a longer view and who are bullish on the near- and mid-term potential of prescription weight-loss drugs, Pfizer offers income plus speculative upside as it builds a position in the GLP-1 space. However, growth-focused investors may be reluctant to tolerate another year of underperformance. Analysts' average 12-month price target implies a little more than 10% potential upside from the stock's current price, alongside a consensus Hold rating. Meanwhile, short interest has been steadily rising as the stock attracts Wall Street bears. Currently, about $3.58 billion of the float is shorted — nearly 84% more than PFE's short position at the end of January 2025.
| 
